Mark Erlander is Chief Executive Officer of Cardiff Oncology, Inc.. Currently has a direct ownership of 24,481 shares of CRDF, which is worth approximately $66,343. The most recent transaction as insider was on Nov 25, 2022, when has been sold 10,000 shares (Common Stock) at a price of $1.43 per share, resulting in proceeds of $14,300. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 24.5K
0% 3M change
0% 12M change
Total Value Held $66,343

Mark Erlander Transaction History

Date Transaction Value Shares Traded Shares Held Form
Nov 25 2022
BUY
Open market or private purchase
$14,300 $1.43 p/Share
10,000 Added 29.0%
24,481 Common Stock
Mar 23 2021
BUY
Open market or private purchase
$9,978 $10.34 p/Share
965 Added 6.25%
14,481 Common Stock
Jan 02 2021
SELL
Payment of exercise price or tax liability
-
113 Reduced 0.83%
13,516 Common Stock
Jan 02 2021
BUY
Exercise of conversion of derivative security
-
260 Added 1.87%
13,629 Common Stock
ME

Mark Erlander

Chief Executive Officer
San Diego, CA

Track Institutional and Insider Activities on CRDF

Follow Cardiff Oncology, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CRDF shares.

Notify only if

Insider Trading

Get notified when an Cardiff Oncology, Inc. insider buys or sells CRDF shares.

Notify only if

News

Receive news related to Cardiff Oncology, Inc.

Track Activities on CRDF